In vitro activities of piperacillin against beta-lactamase-negative ampicillin-resistant Haemophilus influenzae
Yoshiro Morikawa1, Miyoshi Kitazato, Junichi Mitsuyama
1Yodogawa Christian Hospital, Higashiyodogawa-ku, Osaka, Japan.
Abstract:
The in vitro activities of piperacillin (PIP) against beta-lactamase-negative ampicillin (AMP)-resistant (BLNAR) Haemophilus influenzae were compared with those of cefotaxime (CTX) and ceftriaxone (CRO), and the potency of PIP as therapy for meningitis caused by BLNAR is also discussed. PIP showed good activity (MIC at which 90% of strains are inhibited, 0.25 micro g/ml) against 69 BLNAR strains, and its activity was comparable to that of CRO and superior to that of CTX. No significant correlation was observed between the MICs of PIP and CTX or CRO or AMP, whereas a high correlation was observed between the MICs of CTX and CRO. In the killing study, PIP showed potent bactericidal activity compared with those of CTX and CRO. By microscopic examination, PIP caused the formation of a spindle and short filamentous cells with bulges and induced cell lysis in BLNAR strains, while treatment with CTX and CRO resulted in the formation of large, spherical cells without any obvious lysis. The affinity of Bocillin FL, a fluorescent penicillin used for determination of the 50% inhibitory concentration (IC(50)s) for penicillin-binding proteins (PBPs), to PBPs 3a and 3b of BLNAR strains was drastically decreased compared with that to an AMP-susceptible strain (ATCC 33391). In the case of the BLNAR strains, the IC(50)s for PBPs 1a, 1b, and 2 were similar to those for the PBPs of ATCC 33391. Since the affinity of binding to PBPs 3a and 3b of the BLNAR strains decreased drastically, the second targets among the PBPs were PBP 2 for PIP, PBP1 (1a and 1b) for CTX and CRO. In conclusion, PIP showed excellent activities against BLNAR strains in a manner different from those of cephem antibiotics, suggesting that it could be a candidate therapeutic agent for the treatment of meningitis caused by BLNAR strains.
Insights
Piperacillin (PIP) demonstrates potent activity against beta-lactamase-negative ampicillin-resistant (BLNAR) Haemophilus influenzae, showing promise for treating meningitis. Its bactericidal effects and unique mechanism differ from other antibiotics.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Beta-lactamase-negative ampicillin-resistant (BLNAR) Haemophilus influenzae poses a treatment challenge.
- Understanding antibiotic activity against BLNAR strains is crucial for effective therapy.
Purpose of the Study:
- To compare the in vitro activity of piperacillin (PIP) with cefotaxime (CTX) and ceftriaxone (CRO) against BLNAR H. influenzae.
- To evaluate the potential of PIP in treating meningitis caused by BLNAR strains.
Main Methods:
- In vitro susceptibility testing (MIC determination) for PIP, CTX, and CRO against BLNAR strains.
- Bactericidal activity assessment and microscopic examination of bacterial morphology post-treatment.
- Penicillin-binding protein (PBP) affinity studies using Bocillin FL.
Main Results:
- PIP exhibited potent activity (MIC90 = 0.25 micro g/ml), comparable to CRO and superior to CTX.
- PIP demonstrated strong bactericidal activity and induced cell lysis, unlike CTX and CRO.
- Reduced affinity of PIP to PBPs 3a and 3b in BLNAR strains was observed, with PBP 2 as a secondary target.
Conclusions:
- Piperacillin shows excellent in vitro activity against BLNAR strains through a distinct mechanism compared to cephem antibiotics.
- PIP is a potential therapeutic candidate for meningitis caused by BLNAR H. influenzae.
More Related Videos
Related Concept Videos
Inhibitors of Gram-positive Cell Wall Synthesis
Production of Antibiotics
Mechanism of Antibiotic Resistance in MRSA


